



## **TSO<sub>3</sub> Announces the Vote Results from its Annual Meeting of the Shareholders and the Appointment New Chairperson**

**Quebec City, Canada and Myrtle Beach, United States, May 10 2018** – TSO<sub>3</sub> Inc. (TSX: TOS), (“TSO<sub>3</sub>” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated April 3, 2018, were elected as directors of TSO<sub>3</sub>. In addition, all other proposals submitted by management were approved.

### Election of Directors

Based on the proxies received and the votes on a show of hands, the following individuals were elected as directors of the Corporation until the next annual shareholders’ meeting. Accordingly, the results are set out below:

Name	Votes for	% for	Withheld	% withheld
Douglas Dieter	36,802,968	96.38	1,382,514	3.62
Claude Michaud	34,183,227	89.52	4,002,255	10.48
Jeffrey Pompeo	34,146,552	89.42	4,038,930	10.58
Jean-Pierre Robert	34,184,837	89.52	4,000,645	10.48
Linda Rosentstock	36,305,700	95.08	1,879,782	4.92
Richard M. Rumble	29,722,388	77.84	8,463,094	22.16
Steve West	34,170,938	89.49	4,014,544	10.51

### Other Proposals

Proposals	Votes for	% for	Votes against	% against	Withheld	% withheld
Appointment of Independent Auditors	44,602,998	97.42	0	0	1,181,127	2.58
Advance Notice By-Law	27,587,290	72.25	10,598,192	0	0	0

Final voting results on all matters voted at the Annual Meeting of Shareholders held on May 9, 2018, will be filed on SEDAR ([www.sedar.com](http://www.sedar.com)) under the name TSO<sub>3</sub>.

### Appointment of a New Chairperson

TSO<sub>3</sub> is also pleased to announce that the board appointed Dr. Linda Rosenstock as Chairperson of the Board of Directors. Dr. Rosenstock is a physician executive in academia and government, with broad experience in clinical care, health care delivery, population health, research and health and regulatory policy.

### **About TSO<sub>3</sub>**

Founded in 1998, TSO<sub>3</sub>'s activities encompass the sale, production, maintenance, research, development, and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently

used in hospitals. TSO<sub>3</sub> also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO<sub>3</sub>, visit the Company's website at [www.tso3.com](http://www.tso3.com).

*The statements in this release and oral statements made by representatives of TSO<sub>3</sub> relating to matters that are not historical facts are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the limited history of sales or distribution of the Company, the ability of the Company to obtain the required regulatory clearances to market its products, general business and economic conditions, the condition of the financial markets, the ability of TSO<sub>3</sub> to obtain financing on favourable terms and other risks and uncertainties. Although TSO<sub>3</sub> believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The complete versions of the cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect TSO<sub>3</sub>'s actual or projected results are included in the Management's Discussion and Analysis for the year ended December 31, 2017, which is available on the Company's website. The forward-looking statements contained in this press release are made as of the date hereof, and TSO<sub>3</sub> does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless expressly required by applicable securities laws.*

- 30 -

**Source: TSO<sub>3</sub> Inc.**

**For further information**

**Company Contacts:**

R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, Email: [info@tso3.com](mailto:info@tso3.com)

Glen Kayll, CFO, Tel: 418 651-0003, Email: [info@tso3.com](mailto:info@tso3.com)

**Investor Relations:**

Gilmartin Group, Greg Chodaczek, Tel: 610-368-6505, Email: [Greg@gilmartinir.com](mailto:Greg@gilmartinir.com)

Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, Email: [bmire@renmarkfinancial.com](mailto:bmire@renmarkfinancial.com)